文献速递中枢神经肿瘤放疗

多参数磁共振引导高剂量响应适应性放疗联合替莫唑胺治疗新诊断胶质母细胞瘤的2期研究中期分析

A Phase 2 Study of Multiparametric Magnetic Resonance Imaging-Guided High-Dose Response-Adaptive Radiation Therapy With Concurrent Temozolomide in Patients With Newly Diagnosed Glioblastoma: Results From an Interim Analysis.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2025-03-08

这项单臂2期研究在新诊断胶质母细胞瘤切除术后患者中,采用高b值弥散加权和动态对比增强灌注磁共振识别高细胞和高灌注肿瘤体积,进行剂量强化放化疗并中期再评估后对持续和新生区域加量。中期分析纳入30例中的16例,中位年龄58岁(范围29-75),69%为男性,计划中期分析确定神经毒性和安全性可接受,继续入组。

要点

  • 16例可评估患者中位年龄58岁(范围29-75),69%为男性,50%全切,19%MGMT甲基化。
  • 放疗前TVHCV/TVCBV中位6.9 cc(范围1.9-42.8),其中30%(范围1%-72%)为非强化。
  • 中期再评估时TVHCV/TVCBV中位4.2 cc(范围0.8-34.3),47%(范围3%-74%)为非强化。

主要发现

  • 中期分析纳入16例,中位年龄58岁(范围29-75),69%为男性,无患者仅接受活检,50%全切,19%为O6-甲基鸟嘌呤-DNA甲基转移酶甲基化肿瘤。
  • 放疗前TVHCV/TVCBV中位6.9 cc(范围1.9-42.8),非强化部分占30%(范围1%-72%);中期再评估时中位4.2 cc(范围0.8-34.3),非强化部分占47%(范围3%-74%)。
  • 从放疗前持续至中期的TVHCV/TVCBV为2.3 cc(范围0-24.2),初始区域外新发1.8 cc(范围0.3-20.6)。
  • 所有患者均完成自适应再计划加量且无中断,计划中期分析确定神经毒性率和安全性可接受以继续入组。

关键数值与推荐

  • TVHCV/TVCBV联合靶区放疗剂量为50 Gy分20次(2.5 Gy/次),中期再评估后对持续和新发TVHCV/TVCBV加量30 Gy分10次(3 Gy/次)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Biologically-informed radiation therapy (RT) targeting an adversely prognostic hypercellular/hyperperfused imaging phenotype in patients with newly diagnosed glioblastoma (GBM) may improve outcomes by identifying emerging regions of treatment resistance associated with overall survival, and is under investigation in an ongoing phase 2 trial (NCT04574856) of individualized, response-adaptive RT. METHODS AND MATERIALS: In this single-arm phase 2 study, patients with newly diagnosed GBM after resection undergo dose-intensified chemoradiation targeting the residual hypercellular (TVHCV, 2 SD above mean intensity contralateral normal brain) and hyperperfused tumor volume (TVCBV, 1 SD above contralateral normal frontal lobe gray matter) identified using high b-value diffusion-weighted and dynamic contrast-enhanced perfusion magnetic resonance imaging. The combination of TVHCV and TVCBV (TVHCV/TVCBV) is treated to 50 Gy in 20 fractions (2.5 Gy/fraction), and after mid-RT reassessment, the persistent and developing TVHCV/TVCBV is treated to 30 Gy in 10 fractions (3 Gy/fraction). The primary endpoint is improvement in overall survival, with planned interim safety analysis. RESULTS: At interim analysis, 16 of 30 patients were enrolled. Median age was 58 years (range, 29-75) and 69% were male. No patient underwent biopsy only, and 50% had gross total resection; 19% had O6-methylguanine-DNA methyltransferase methylated tumors. Median TVHCV/TVCBV was 6.9 cc (range, 1.9-42.8) pre-RT and 30% (range, 1%-72%) was nonenhancing. By mid-RT, TVHCV/TVCBV was reduced to 4.2 cc (range, 0.8-34.3) and 47% (range, 3%-74%) was nonenhancing. The TVHCV/TVCBV persisting from pre-RT to mid-RT was 2.3 cc (range, 0-24.2), with an additional 1.8 cc (range, 0.3-20.6) newly developing outside of the initial region. All patients underwent adaptive replanning for boost without interruption. Planned interim analysis determined an acceptable rate of neurologic toxicity and safety to continue enrollment. CONCLUSIONS: Individualized, response-adaptive chemoradiation using an advanced imaging biomarker to assess emerging and especially nonenhancing regions of treatment resistance in patients with GBM is feasible, with short-term safety and longer-term efficacy outcomes anticipated with completion of accrual.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Kim MM, Aryal MP, Suresh K, et al. A Phase 2 Study of Multiparametric Magnetic Resonance Imaging-Guided High-Dose Response-Adaptive Radiation Therapy With Concurrent Temozolomide in Patients With Newly Diagnosed Glioblastoma: Results From an Interim Analysis. Int J Radiat Oncol Biol Phys. 2025. PMID: 40058709. doi:10.1016/j.ijrobp.2025.02.020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。